Peripherally inserted central catheters (PICCs) have become popular for long courses of intravenously administration of antibiotics. Although these devices are generally regarded as safe, thrombotic complications have been associated with their use. In a retrospective review, 51 (2.47%) of 2063 patients who had a PICC placed during 1994-1996 were found to have developed a total of 52 PICC-associated venous thromboses (VTs). Two patients received the diagnosis of pulmonary embolism that was a complication of VT. Risk factors for VT identified by multiple logistic regression analysis were younger age, history of VT, discharge to a skilled-nursing facility, and therapy with amphotericin B. VT is a significant complication of PICC placement. It may occur more frequently than previously recognized and may be complicated by pulmonary embolism. Clinicians should maintain a high index of suspicion, especially for high-risk patients.
Peripherally inserted central catheters (PICCs) have become popular during recent years for outpatient administration of various medications and parenteral nutrition. PICCs are generally considered to be safe devices. A number of complications are known to be associated with their use, including infection, venous thrombosis (VT), pulmonary embolism, phlebitis, catheter malposition, and catheter fracture. Little is known about the rate of thrombotic complications associated with PICCs; the reported incidence varies from 0.3% [1] to 56% [2] . The significant difference in these rates is probably related to the specific populations studied, location of the catheter tip, diagnostic modalities used, and other factors. Furthermore, higher rates were observed in studies in which patients with PICCs were screened for thrombosis than in studies that evaluated only symptomatic patients. To delineate the incidence of and risk factors for VT associated with PICCs, we retrospectively reviewed data collected at the Cleveland Clinic Foundation (CCF) over a period of 34 months. A portion of this study has been published elsewhere in abstract form [3] .
PATIENTS AND METHODS
We included in our study all patients at CCF for whom a PICC was inserted for intravenous administration of antibiotics from 1 January 1994 through 31 October 1996. We obtained a complete list of these patients from a computer database. A list of all upper-extremity ultrasonographs and venograms that were positive for a VT during the same period was obtained from a da- The brand of PICCs used in our institution during the study period was Per-Q-Cath (Bard), a single-lumen catheter. The sizes of these catheters were 3.0 Fr or 4.0 Fr. PICCs were inserted by members of a team of registered nurses, known as the "PICC team," each of whom had been trained in the same technique of insertion. Strict aseptic conditions were used during each procedure: sterile gloves, gowns, and face masks were worn, and careful skin cleaning and draping of the procedure area were performed. Chest radiography was done to ensure proper tip location after the procedure was completed. All patients who were receiving intravenously administered antibiotics via PICC were followed up in the outpatient division of the infectious diseases department.
We retrospectively reviewed the medical records of the case patients to confirm the presence of thrombosis, and we collected the following data: the diagnosis that led to administration of outpatient parenteral antibiotic therapy (OPAT), the antibiotics used during OPAT, discharge information, clinical manifestations of and therapy for the thrombotic complication, and evidence of pulmonary embolism diagnosed either by ventilation-perfusion scan or pulmonary angiography. We also completed a case-control study. We identified 107 control patients, who were randomly chosen from patients who had a PICC placed during the same period (i.e., 1 January 1994 through 31 October 1996) for intravenously administered antibiotic therapy and who had no subsequent evidence of symptomatic thrombotic events. We excluded as control patients those who had the PICC inserted for !21 days, to reduce the bias of choosing control patients who might have had late thrombotic events [1] , and also excluded those for whom no follow-up data were available.
Predisposing conditions were also noted for both groups, including a history of deep VT and pulmonary embolism, malignancy, and hypercoagulable state (i.e., deficiencies in lupus anticoagulant, protein C, protein S, or antithrombin III); a history of neuromuscular disease or cerebrovascular accident; and the presence of AIDS.
We classified an upper-extremity VT (UEVT) as "superficial" if it involved the cephalic, basilic, external jugular, or axillary veins and did not extend into the innominate, subclavian, or internal jugular veins. We classified a UEVT as "deep" if the thrombus extended into the subclavian vein or was located more centrally. Therapy for the thrombotic or embolic events was one of the following: intravenously administered heparin followed by orally administered warfarin, orally administered warfarin alone, subcutaneously administered heparin alone, thrombolysis or thrombectomy, caval filter placement, or observation only.
Statistical analysis was performed by SPSS, version 7.0 (SPSS). Univariate logistic regression was used to identify risk factors for VT at the 0.05 and at 0.10 a level (Wald x 2 test) to gather a pool of potential risk factors in the stepwise model building process. Multiple logistic regression analysis was then used to build a model of predictors of thrombosis.
RESULTS

Case patients.
A total of 2063 PICCs were inserted during the 34-month study period. Fifty-one patients developed 52 UEVTs, for an incidence of 2.47%. Twenty-nine (55.8%) of 52 UEVTs were deep, and 23 (44.2%) of 52 were superficial (table  1) . The thrombotic events were diagnosed by duplex ultrasonography in 48 cases and by venography in 4 cases. The mean time (‫ע‬SD) to diagnosis after PICC placement was days (median, 13 days). There was no significant 18.7 ‫ע‬ 17.5 difference in the mean time to diagnosis between deep and superficial UEVT. Thirty-four percent of the thrombotic events were diagnosed by the end of the first week after PICC insertion, 55% were diagnosed by the end of the second week, and 75% were diagnosed by the end of the third week (figure 1). By use of ventilation-perfusion scans, pulmonary embolism was diagnosed in 2 patients (3.8% of the patients with UEVT). No adverse outcomes other than pulmonary embolism were noted. Specifically, there was no associated bacteremia or suppurative thrombophlebitis in any of the case patients.
Forty-one patients with UEVT received some form of anticoagulation therapy (intravenously administered heparin fol- ). Furthermore, after running the P p .006 model in a stepwise process, HIV infection did not add significant independent information to the logistic regression model, but AmB therapy did.
DISCUSSION
With the advent of managed care, and with the increasing pressure on doctors to keep resource use to a minimum while providing quality health care, the number of patients receiving OPAT has increased in recent years. A safe and reliable venous access device is vital to the clinical success and cost-effectiveness of OPAT. In the early years of these programs, peripheral vein catheters were commonly used for home or outpatient therapy; more recently, tunneled catheters, implanted infusion devices, midline catheters, and PICCs have emerged as viable alternatives to heparin locks. Ng et al. [4] analyzed the safety and costs of the use of PICCs, and their conclusions strongly favored PICCs as alternatives to other vascular access devices. Although PICCs are generally considered to be safe devices, they are associated with a number of known complications, including phlebitis, exit-site infections, bacteremia with or without rightside endocarditis, VT, and catheter embolism [1, 5, 6] .
VT of the upper extremities has been previously reported with the use of PICCs. Criteria for diagnosis of UEVT and discrimination between superficial and deep VT (particularly as related to distal cephalic VT) have not been fully standardized. Several studies have examined PICC-related VT, and incidences have varied from 0.3% to 56%. A low incidence was found in retrospective studies [1, 5, 7, 8] in which only symptomatic VTs were identified. A higher incidence of PICC-related VT has been noted in prospective studies [2] in which symptomatic and asymptomatic VTs were identified. Because of the retrospective nature of our study, the observed incidence of 2.5% may be an underestimation of the true prevalence of PICC-related VT. There were 2 documented events of pulmonary embolism (among 52 thrombotic events), which is a complication well described in patients with UEVT [9, 10] . Other sequelae of UEVT, including recurrent venous thromboembolism and late postthrombotic syndrome, may be observed, but they did not develop in the patients we studied.
Some studies have examined risk factors for UEVT in patients with cancer who have tunneled central catheters [11] , but few studies have looked at risk factors associated with the development of UEVT in patients with PICCs. Most studies examined catheter-tip location and demonstrated an increased risk of thrombosis among patients in whom the catheter tip was located proximal to the lower third of the superior vena cava [2, 12, 13] . The clustering of UEVTs occurring early in the course of OPAT among our patients suggests that there were mechanical complications related to the insertion procedure (i.e., the number of insertion attempts, the position of the catheter tip, and manipulation of the catheter after insertion). This association was also suggested by Loughran and Borzatta [1] , who concluded that early phlebitis is attributable to the mechanics of insertion, whereas late phlebitis is the result of chemical and patient-specific causes. In our review, data were not available regarding mechanical complications related to the insertion procedure. Several risk factors for PICC-related VT were identified in our study. Receipt of treatment with AmB was an independent risk factor for UEVT. The increased risk of developing deep or superficial VT from hypertonic solutions [14] or low pH [15] due to endothelial damage and subsequent thrombus formation is a well-known phenomenon [16] . Maddux and Barriere [15] , in their review of complications of AmB therapy, suggested that the pH of AmB in dextrose 5% solution may be too acidic and may lead to coagulation of the colloid and to vein irritation. On the other hand, Gazitua et al. [14] found that solutions with an osmolarity of !450 mOsm/L demonstrated the lowest risk of phlebitis; those with an osmolarity of 450-600 mOsm/L were associated with moderate risk, and solutions with an osmolarity of 1600 mOsm/L always resulted in phlebitis. The osmolarity of AmB in solution is usually ∼256 mOsm/L with a pH of 6, which decreases the likelihood that the UEVT is due to the hypertonicity of the drug or to the pH, especially given that AmB is hypotonic and has a pH closer to the physiologic pH when compared with other antibiotics commonly used, such as vancomycin (osmolarity, 291 mOsm/L; pH 4), piperacillin (osmolarity, 452 mOsm/L; pH 5.5-7.5), acyclovir (osmolarity, 342 mOsm/L; pH 10-11), and ganciclovir (osmolarity, 320 mOsm/L; pH 11). Therefore, we believe that the association of UEVT with AmB is best explained by the known thrombogenic effect of this antifungal medication, which is the result of its irritative effects on the veins.
A history of deep VT was associated with an increased risk of developing a new UEVT. This is a well-established risk factor for thrombotic complications. A recent prospective study conducted by Hansson et al. [17] found that, among other risk factors, a history of a venous thromboembolism predicted an independently increased risk of recurrent events in a multivariate survival analysis.
In our study, we also found that patients who were discharged to a skilled-nursing facility were more likely to develop a UEVT. We speculate that these patients, who usually required help with their daily activities and with antibiotic administration, had decreased mobility in their upper extremities, which predisposed them to develop VT.
Finally, case patients were younger than control patients (mean age, 48.1 vs. 54.1 years;
). This may be because P p .03 there were a higher number of HIV-infected patients among the case patients we studied than among the control patients; this finding was not statistically significant but showed a definite trend ( ). HIV-infected patients are known to be at P p .06 higher risk for VT, especially when they are in the advanced stages of disease [18, 19] . It is speculated that multiple mechanisms are responsible for the hypercoagulable state associated with HIV, such as hematological abnormalities (e.g., presence of antiphospholipid antibodies and deficiencies of protein C, protein S, and antithrombin III) [18, 19, 20] and malignancies [21, 22] .
The main limitation of our retrospective review is that the incidence of UEVT was probably underestimated, because only symptomatic UEVTs were investigated. In addition, diagnostic evaluation for UEVT and treatment decisions for patients found to have VT were dependent on the physician.
CONCLUSION
It is important to be aware of UEVT as a potential complication of use of PICCs. Superficial and deep VT may occur more frequently than previously recognized and may be complicated by pulmonary embolism, a potentially life-threatening event.
The data in our study regarding the incidence of PICC-related UEVTs were disturbing enough to stimulate a prospective trial, currently under way, to examine the associated risk factors and incidence of symptomatic and asymptomatic UEVT associated with use of PICCs. Preliminary results suggest that the incidence of VT is much higher than one would expect, especially in asymptomatic patients [23] . We believe that thrombotic events associated with the use of PICCs are underdiagnosed because of the lack of symptoms or signs to prompt the clinician to order a diagnostic test. The clinician should maintain a high index of suspicion in order to increase the chances for an early diagnosis. Furthermore, future studies are warranted to assess the costs and benefits of some form of prophylaxis for PICCrelated UEVT, especially in high-risk patients.
